Financial results: Rua Bioscience by Martin Lane January 29, 2025January 29, 2025 New Zealand firm Rua Bioscience has achieved unaudited revenue of NZ$694k for the six months ending […]
We’re on a journey, says Rua chair, as capital raise falls short by Steve Jones December 7, 2024April 11, 2025
Formal mediation fails to resolve Cann Group and Rua legal dispute but talks continue by Steve Jones October 30, 2024October 30, 2024
Financial results: Rua Bioscience; Elixinol Wellness; Argent Biopharma; Wellnex Life; InhaleRx; Bioxyne by Martin Lane and Steve Jones September 2, 2024September 3, 2024
Company news: Rua Bioscience; Avecho; Bioxyne/BLS; iX Biopharma; Ecofibre; Zelira by Steve Jones and Martin Lane August 28, 2024January 13, 2025
Company news: Bioxyne/BLS; Rua Bioscience; Botanix; Melodiol Global Health; Zelira; Argent BioPharma by Martin Lane and Steve Jones April 16, 2024July 16, 2024
Cann Group vows to ‘vigorously’ defend Rua claims as contract dispute goes legal by Steve Jones February 16, 2024November 25, 2024
Company news: Bioxyne/BLS; Wellnex Life; Elixinol Wellness; Althea; Health House; Rua Bioscience by Steve Jones and Martin Lane February 7, 2024November 25, 2024
Company news: Rua Bioscience; IDT Australia; Emyria; Elixinol Wellness; Neurotech; Hygrovest; Releaf Group/ICCM; Botanix by Martin Lane August 30, 2023April 30, 2024
Company news: MedReleaf; Vitura Health; MGC Pharma; Rua Bioscience by Martin Lane April 13, 2023April 30, 2024
